首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1535600

甲胺蝶呤藥物市場 - 依適應症（牛皮癬、癌症、類風濕關節炎）、藥物類型（品牌、學名藥）、藥物劑型（錠劑、液體、注射）、給藥途徑（口服、皮下）、配銷通路- 全球預測（2024年 -第2032章

Methotrexate Drugs Market - By Indication (Psoriasis, Cancer, Rheumatoid Arthritis), Drug Type (Branded, Generic), Drug Form (Tablet, Liquid, Injectable), Route of Administration (Oral, Subcutaneous), Distribution Channel- Global Forecast (2024 - 2032)

出版日期: 2024年06月05日 | 出版商:

Global Market Insights Inc. | 英文 265 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

由於老年人口不斷成長，2024 年至 2032 年全球甲胺蝶呤藥物市場複合年成長率將達到 3.1%。據世界衛生組織稱，全球60 歲以上人口比例預計將增加近一倍，從2015 年的12% 上升到2050 年的22%。階層-收入國家。

隨著年齡的成長，他們更容易患癌症和自體免疫疾病等慢性疾病，包括類風濕性關節炎和牛皮癬，這些疾病通常用甲氨蝶呤治療。老年人數量的不斷增加，特別是在低收入和中等收入國家，推動了對有效治療方案的需求。此外，醫療基礎設施的進步和老年人獲得醫療服務的改善進一步促進了甲氨蝶呤藥物的採用，支持了市場的擴張。

整個甲胺蝶呤藥物產業根據適應症、藥物類型、劑型、給藥途徑、配銷通路和地區進行分類。

從 2024 年到 2032 年，學名藥領域將經歷顯著成長。對學名藥的需求是由於學名藥與品牌藥的功效和安全性相當，加上成本較低，從而推動市場擴張。

2024-2032 年期間，零售藥局將在甲胺蝶呤藥物的分銷中發揮至關重要的作用。零售藥局提供方便的藥物取得，確保患者可以輕鬆獲得處方。零售藥局的廣泛覆蓋範圍與個人化客戶服務相結合，提高了患者對甲氨蝶呤治療的依從性，從而促進了市場成長。

由於醫療基礎設施的改善、醫學研究投資的增加以及癌症和自體免疫疾病等慢性病的高盛行率，亞太地區甲氨蝶呤藥物市場預計在 2024 年至 2032 年期間實現顯著成長。強而有力的監管架構確保藥品的品質和安全，促進廣泛使用。此外，政府對醫療保健計劃的支持以及領先製藥公司的存在推動了創新和生產，促進了該地區甲氨蝶呤市場的強勁成長。

產業生態系統分析
產業影響力
- 成長動力
  - 癌症盛行率增加
  - 使用甲氨蝶呤藥物的持續研究和開發
  - 不斷成長的技術進步和對個人化醫療的需求
- 產業陷阱與挑戰
  - 不良反應和安全問題
  - 有限的報銷和承保政策
成長潛力分析
技術景觀
監管環境
甲氨蝶呤的臨床試驗
2023 年定價分析
- 按地區
- 按關鍵人物
未來市場趨勢
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司市佔率分析
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按指標分類，2021 - 2032 年

主要趨勢
牛皮癬
類風濕關節炎
癌症
其他適應症

第 6 章：市場估計與預測：按藥物類型，2021 - 2032 年

主要趨勢
品牌化
通用的

第 7 章：市場估計與預測：按藥物劑型，2021 - 2032 年

主要趨勢
藥片
液體
可注射

第 8 章：市場估計與預測：按管理途徑，2021 - 2032 年

主要趨勢
口服
皮下
肌肉注射
靜脈

第 9 章：市場估計與預測：按配銷通路分類，2021 - 2032 年

主要趨勢
醫院藥房
零售藥局
網路藥局

第 10 章：市場估計與預測：按地區，2021 - 2032

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 11 章：公司簡介

Accord Healthcare
Amneal Pharmaceuticals LLC
Apotex Inc.
Cipla Limited
Dr. Reddy's Laboratories Ltd.
Hikma Pharmaceuticals PLC
Intas Pharmaceuticals Ltd.
Lupin Limited
Merck KGaA
Novartis AG
Pfizer Inc.
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
Viatris Inc.
Zydus Cadila

簡介目錄

Product Code: 9756

Global Methotrexate Drugs Market will depict 3.1% CAGR from 2024 to 2032, credited to the growing geriatric population. According to the WHO, the proportion of the global population over 60 years old is expected to almost double, rising from 12% in 2015 to 22% by 2050. Additionally, by 2050, 80% of older individuals will reside in low- and middle-income countries.

As people age, they become more susceptible to chronic conditions such as cancer and autoimmune diseases, including rheumatoid arthritis and psoriasis, which are commonly treated with methotrexate. The increasing number of older adults, particularly in low- and middle-income countries, drives the demand for effective treatment options. Additionally, advancements in healthcare infrastructure and improved access to medical care for the elderly further boost the adoption of methotrexate drugs, supporting market expansion.

The overall Methotrexate Drugs Industry is categorized based on indication, drug type, drug form, route of administration, distribution channel, and region.

The generic drug segment will experience significant growth from 2024 to 2032. Generic methotrexate drugs offer cost-effective treatment options, increasing accessibility and affordability for patients. The demand for generic drugs is propelled by their equivalence in efficacy and safety to branded drugs, in line with lower costs, driving market expansion.

Retail pharmacies will play a crucial role in the distribution of methotrexate drugs during 2024-2032. Retail pharmacies provide convenient access to medications, ensuring patients can easily obtain their prescriptions. The extensive reach of retail pharmacies, in tandem with personalized customer service, enhances patient adherence to methotrexate treatments, bolstering market growth.

Asia Pacific methotrexate drugs market is set to achieve notable gains throughout 2024-2032, attributed to improving healthcare infrastructure, rising investments in medical research, and a high prevalence of chronic diseases such as cancer and autoimmune disorders. Strong regulatory frameworks ensure the quality and safety of pharmaceutical products, fostering widespread use. Additionally, government support for healthcare initiatives and the presence of leading pharmaceutical companies drive innovation and production, contributing to the robust growth of the methotrexate market in the region.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of cancer
  - 3.2.1.2 Ongoing research and development using methotrexate drugs
  - 3.2.1.3 Rising technological advancements and demand for personalized medicine
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Adverse effects and safety concerns
  - 3.2.2.2 Limited reimbursement and coverage policies
3.3 Growth potential analysis
3.4 Technological landscape
3.5 Regulatory landscape
3.6 Clinical trials on methotrexate
3.7 Pricing analysis, 2023
- 3.7.1 By region
- 3.7.2 By key player
3.8 Future market trends
3.9 Porter's analysis
3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Psoriasis
5.3 Rheumatoid arthritis
5.4 Cancer
5.5 Other indications

Chapter 6 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Branded
6.3 Generic

Chapter 7 Market Estimates and Forecast, By Drug Form, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Tablet
7.3 Liquid
7.4 Injectable

Chapter 8 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Oral
8.3 Subcutaneous
8.4 Intramuscular
8.5 Intravenous

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 Hospital pharmacies
9.3 Retail pharmacies
9.4 Online pharmacies

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

10.1 Key trends
10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Netherlands
- 10.3.7 Rest of Europe
10.4 Asia Pacific
- 10.4.1 Japan
- 10.4.2 China
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 South Korea
- 10.4.6 Rest of Asia Pacific
10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Argentina
- 10.5.4 Rest of Latin America
10.6 Middle East and Africa
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
- 10.6.3 UAE
- 10.6.4 Rest of Middle East and Africa